Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NicOx Data Positive, But Is it Enough?

This article was originally published in The Pink Sheet Daily

Executive Summary

NicOx reported positive blood pressure data for Phase III osteoarthritis candidate naproxcinod, but pooled, post-hoc analyses may not be enough to differentiate the drug.
Advertisement

Related Content

NicOx Buys Back Glaucoma Drug Rights From Pfizer
NicOx Buys Back Glaucoma Drug Rights From Pfizer
NicOx Envisions Co-Commercialization And In-Licensing Strategy Around Naproxcinod
NicOx Envisions Co-Commercialization And In-Licensing Strategy Around Naproxcinod
Naproxcinod Can Win Approval Without Superiority Trial, NicOx Says
NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod
Nervous Times for NDA Sponsors: The New Reality of FDA Drug Reviews
NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?
NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?
NicOx Osteoarthritis NDA Filing On Track Following FDA Correspondence

Topics

Advertisement
UsernamePublicRestriction

Register

PS067142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel